Lactobacillus paracasei
Lactobacillus paracasei Lpc-37
Lpc-37 (ATCC SD5275)
Supporting everyday immune resilience and shortening the duration of common infections.
Quick Overview
At a Glance
Researched Benefits
- Clinically studied for immune system support — helping your body stay resilient during cold and flu season.
- Shown to help shorten the duration of gut infections and reduce diarrhea when taken alongside antibiotic treatment.
- One of the most rigorously safety-tested probiotic strains available, with genomic and toxicology data confirming its clean bill of health.
- Emerging research links it to stress resilience and cognitive benefits via the gut-brain axis, making it a genuinely well-rounded strain.
Usage & Application
Clinically Studied Dosage
2–10 Billion CFU/day (typically as part of a multi-strain formula)
Available Forms
Clinical Evidence
Everyday Immune Support Backed by Clinical Research: Lactobacillus paracasei Lpc-37
Lactobacillus paracasei Lpc-37 is a naturally occurring lactic acid bacterium that was first isolated from human intestinal samples and has since become one of the most studied probiotic strains in clinical research. It belongs to the Lactobacillus paracasei family — a group of bacteria that thrive in the human gut and have been used safely in fermented foods for centuries. What makes Lpc-37 special is how it behaves once it reaches your intestines: it acts like a skilled diplomat between your gut and your immune system, helping to calibrate your body's inflammatory responses without pushing them to extremes. The gut is home to over 70% of your entire immune system, and Lpc-37 is one of the strains that researchers believe actively 'educates' immune cells in that environment. It survives the journey through stomach acid with impressive resilience — studies using simulated digestive passages show it reaches the colon in detectable numbers, where it then gets to work interacting with the local microbiome.
The health benefits of Lpc-37 stretch across several areas, but its reputation is built most firmly on immune support. In clinical research involving both healthy adults and people with chronic skin inflammation like atopic dermatitis (eczema), Lpc-37 supplementation was found to modulate the activity of key immune cells — essentially teaching the immune system to respond more calmly and precisely. For people with eczema, supplementing with Lpc-37 alongside other strains showed a measurable trend toward reduced skin symptom severity over eight weeks, with shifts in certain immune cell behavior that distinguished probiotic users from those on placebo. Beyond skin and allergic conditions, this strain has appeared in clinical trials focused on gut health during and after antibiotic treatment — a scenario where the microbiome takes a serious hit. In one randomized trial, a multi-strain formula containing Lpc-37 significantly shortened the duration of diarrhea linked to a difficult gut infection, cutting the time people spent feeling miserable by days compared to a placebo group. Separately, research in young children found that daily Lpc-37 supplementation over nine months was associated with a reduced risk of diarrhea and fever episodes during high-risk seasons, with the strain influencing beneficial short-chain fatty acid production in the gut. There is also intriguing early-stage research suggesting a gut-brain connection: in a systematic animal screening study testing twelve different probiotic strains, Lpc-37 stood out as one of only four strains able to prevent stress-related anxiety and depression-like behaviors from developing — and it was the only one to also show improvements in memory and cognition under chronic stress conditions.
From a safety standpoint, Lpc-37 has one of the most thoroughly documented safety profiles in the probiotic world. Comprehensive testing — including genomic analysis, toxin-gene screening, antibiotic-resistance profiling, and high-dose animal studies — found no red flags, and the strain carries no transferable antibiotic-resistance genes. In human tolerability studies, participants taking high-dose multi-strain formulas containing Lpc-37 consistently completed trials with no serious adverse events, and the most commonly reported side effects were mild and temporary digestive adjustments. Lpc-37 is most commonly found in multi-strain probiotic supplements, particularly alongside Lactobacillus acidophilus NCFM and Bifidobacterium lactis strains, where research suggests the combination has a synergistic effect on gut microbiota and metabolic activity — including a notable boost in butyrate production, which is a key fuel for gut-lining cells. It is suitable for healthy adults across all age groups, including older adults who may be on antibiotic therapy, and has also been studied in children as young as two. People with compromised immune systems should always consult a physician before starting any probiotic. For best results, Lpc-37 is typically taken daily with a meal, in a refrigerated capsule or powder form, to maximize the number of live bacteria reaching the gut.
Common Questions
Frequently Asked Questions
Sources
Scientific References
Curated By

Clara Hayes
Lead Research Editor
Clara leads the curation and verification of microbiome research for our platform. With extensive experience in translating complex scientific literature into accessible insights, she ensures every strain profile is grounded in peer-reviewed evidence and contextual accuracy.
Medical Disclaimer
The information provided on probioticstrains.com is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Strain profiles and clinical summaries are compiled from published peer-reviewed literature. While we may evaluate or highlight specific commercial formulations, our insights are always grounded in available scientific evidence. Always consult a qualified healthcare provider before starting, changing, or stopping any supplement or health regimen.